UKCB Medication-related osteonecrosis of the jaw (MRONJ) guidance_Dec 2019
This guidance has been produced by a multidisciplinary working party on behalf of the UK Chemotherapy Board which includes specialist representation from medical, dental and nursing teams across the UK.
It has been endorsed by the Clinical Standards Committee of the Faculty of Dental Surgery of the Royal College of Surgeons of England.
It is common practice in oncology to prescribe bone-modifying agents (BMAs) or anti-angiogenic drugs (AADs) for a range of cancers. The association of these drugs in medication-related osteonecrosis of the jaw (MRONJ) has led to a wealth of published guidance. However, much of this guidance is focused and weighted towards the dental specialty with minimal information to assist oncologists. As regular prescribers of these medications, it is essential that appropriate information in both preventing and managing MRONJ is available for responsible treatment planning. Hence, this guidance has been assembled to aid oncologists and the wider team in understanding the condition and subsequently provide optimum clinical care.
In summary, the guidance focuses on all aspects of MRONJ in relation to oncology patients. It aims to fulfil three functions:
- Primarily, it is a single source of collective information for oncology teams focused around the prevention and management of MRONJ.
- Secondly, it proposes protocols that oncology departments can adapt and amend accordingly to fit local delivery of services.
- Thirdly, it provides a series of simple communication adjuncts that can be adapted to assist communication between the oncology multidisciplinary team, patients, dental practitioners and hospital dental specialists.
Collaboration between the cancer care team, dentists and dental specialists is repeatedly emphasised and encouraged throughout the guidance.
For all documents please visit: https://www.rcplondon.ac.uk/guidelines-policy/medication-related-osteonecrosis-jaw-guidance-oncology-multidisciplinary-team
UKCB Medication-related osteonecrosis of the jaw (MRONJ) guidance_Dec 2019
File type: application/pdf
Download resourceBOPA encourages its members to share helpful documents that can benefit other members. BOPA respects the intellectual property of original authors and requires anyone who uses other members’ work to include an acknowledgment of, or reference to, the source in their version.
DISCLAIMER:
BOPA is not the author or owner of some of the documents published on our website. BOPA as a professional interest group will share documents via its website that are of interest to BOPA members, but has no responsibility for use of the documents and for any recommendations within the documents so members must use these at their discretion. BOPA cannot accept responsibility for any errors or omissions or for any consequences from application of information in the documents attached and make no warranty, expressed or implicit with respect to the contents of this webpage. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site or document(s) downloaded from it.
Posters and abstracts on the BOPA website remain the property of the authors and anyone wishing to reference or share this work must contact the authors directly. Abstracts subsequently published in JOPP follow copyright rules from JOPP.
